These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
489 related articles for article (PubMed ID: 8710369)
1. AML-2 is a potential target for transcriptional regulation by the t(8;21) and t(12;21) fusion proteins in acute leukemia. Meyers S; Lenny N; Sun W; Hiebert SW Oncogene; 1996 Jul; 13(2):303-12. PubMed ID: 8710369 [TBL] [Abstract][Full Text] [Related]
3. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias. Lo Coco F; Pisegna S; Diverio D Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595 [TBL] [Abstract][Full Text] [Related]
4. The t(8;21) fusion protein, AML1/ETO, transforms NIH3T3 cells and activates AP-1. Frank RC; Sun X; Berguido FJ; Jakubowiak A; Nimer SD Oncogene; 1999 Mar; 18(9):1701-10. PubMed ID: 10208431 [TBL] [Abstract][Full Text] [Related]
5. The ETO portion of acute myeloid leukemia t(8;21) fusion transcript encodes a highly evolutionarily conserved, putative transcription factor. Erickson PF; Robinson M; Owens G; Drabkin HA Cancer Res; 1994 Apr; 54(7):1782-6. PubMed ID: 8137293 [TBL] [Abstract][Full Text] [Related]
6. The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B. Frank R; Zhang J; Uchida H; Meyers S; Hiebert SW; Nimer SD Oncogene; 1995 Dec; 11(12):2667-74. PubMed ID: 8545124 [TBL] [Abstract][Full Text] [Related]
7. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Shurtleff SA; Buijs A; Behm FG; Rubnitz JE; Raimondi SC; Hancock ML; Chan GC; Pui CH; Grosveld G; Downing JR Leukemia; 1995 Dec; 9(12):1985-9. PubMed ID: 8609706 [TBL] [Abstract][Full Text] [Related]
8. Analysis of TEL proteins in human leukemias. Poirel H; Lacronique V; Mauchauffé M; Le Coniat M; Raffoux E; Daniel MT; Erickson P; Drabkin H; MacLeod RA; Drexler HG; Ghysdael J; Berger R; Bernard OA Oncogene; 1998 Jun; 16(22):2895-903. PubMed ID: 9671410 [TBL] [Abstract][Full Text] [Related]
9. Rearrangements of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: in vitro and in vivo studies. Zent C; Rowley JD; Nucifora G Leukemia; 1997 Apr; 11 Suppl 3():273-8. PubMed ID: 9209363 [TBL] [Abstract][Full Text] [Related]
10. AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML. Licht JD Oncogene; 2001 Sep; 20(40):5660-79. PubMed ID: 11607817 [No Abstract] [Full Text] [Related]
12. Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells. Wichmann C; Chen L; Heinrich M; Baus D; Pfitzner E; Zörnig M; Ottmann OG; Grez M Cancer Res; 2007 Mar; 67(5):2280-9. PubMed ID: 17332359 [TBL] [Abstract][Full Text] [Related]
13. MYND-less splice variants of AML1-MTG8 (RUNX1-CBFA2T1) are expressed in leukemia with t(8;21). Kozu T; Fukuyama T; Yamami T; Akagi K; Kaneko Y Genes Chromosomes Cancer; 2005 May; 43(1):45-53. PubMed ID: 15723339 [TBL] [Abstract][Full Text] [Related]
14. Ribozymes cleave the AML1/MTG8 fusion transcript and inhibit proliferation of leukemic cells with t(8;21). Matsushita H; Kobayashi H; Mori S; Kizaki M; Ikeda Y Biochem Biophys Res Commun; 1995 Oct; 215(2):431-7. PubMed ID: 7487974 [TBL] [Abstract][Full Text] [Related]
15. Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells. Wang J; Saunthararajah Y; Redner RL; Liu JM Cancer Res; 1999 Jun; 59(12):2766-9. PubMed ID: 10383127 [TBL] [Abstract][Full Text] [Related]
16. The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. Linggi B; Müller-Tidow C; van de Locht L; Hu M; Nip J; Serve H; Berdel WE; van der Reijden B; Quelle DE; Rowley JD; Cleveland J; Jansen JH; Pandolfi PP; Hiebert SW Nat Med; 2002 Jul; 8(7):743-50. PubMed ID: 12091906 [TBL] [Abstract][Full Text] [Related]
17. The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent manner. Elsässer A; Franzen M; Kohlmann A; Weisser M; Schnittger S; Schoch C; Reddy VA; Burel S; Zhang DE; Ueffing M; Tenen DG; Hiddemann W; Behre G Oncogene; 2003 Aug; 22(36):5646-57. PubMed ID: 12944913 [TBL] [Abstract][Full Text] [Related]
18. Detection and subcellular localization of an AML1 chimeric protein in the t(8;21) positive acute myeloid leukemia. Sacchi N; Schiaffonati L; Magnani I; Pappalardo C; Hughes AJ; Darfler M; Hoogeveen AT Oncogene; 1996 Jan; 12(2):437-44. PubMed ID: 8570222 [TBL] [Abstract][Full Text] [Related]
19. AML1 and Pebp2: the gene for a transcription factor is involved in recurring translocations in human acute myeloid leukemia. Rowley JD Jpn J Cancer Res; 1994 Dec; 85(12):inside front cover. PubMed ID: 7852178 [No Abstract] [Full Text] [Related]
20. Interaction and functional cooperation of the leukemia-associated factors AML1 and p300 in myeloid cell differentiation. Kitabayashi I; Yokoyama A; Shimizu K; Ohki M EMBO J; 1998 Jun; 17(11):2994-3004. PubMed ID: 9606182 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]